WBC On A High! ("If Winter Comes" No. 18)

AJ has responded well to treatment and therefor his doc sees no reason to take him off CHOP. Dr. F said he would be crazy to change it since it seems like its working. He did mention that it was going to be administered directly into his bone marrow like in a lumbar punch as well as the IV. I think this is just to target the bone marrow more.

The reason he says that AJ is doing well is because he is feeling better, if the chemo hadn't been working, then he wouldn't feel so good.

Between cycle 3 and 4 we will go down to Houston for a quick visit to do a bone marrow biopsy & PET/CT scan and then see Dr. Fayad a week after that. That way they can really see what the chemo is doing and how he's responding.

PET & CT scan were all negative, no other activity than the one we already know about. :) 

There are a couple of tests that Dr. F wants to do if he can get the paraffin block or unstained slides from Seton. Tests:  Survivin (which is how it sounds, the cells/tumor prone to survive)  and to look for C56 - on outside pathology - outside of the bone marrow.  If he is C 56 positive and/or survivin positive then he would be a candidate for bone marrow transplant. (these are just medical terms that he was using and its the molecular built of the cells) 

If he has to do a bone marrow transplant, Dr. F said that the donor bank would be our best bet …

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap